Home/Hedge Fund Intelligence/Beam Therapeutics Inc.
Nasdaq: BEAMStockForm 13F30 Jun 2026

Hedge funds that hold Beam Therapeutics Inc. Nasdaq: BEAM

CUSIP 07373V105 · who reports it, how much, and how much it matters to them

27 of the 720 hedge fund managers we track reported shares of Beam Therapeutics Inc. (Nasdaq: BEAM) on Form 13F for 30 June 2026. Between them they reported USD 696m. The largest position belongs to Farallon Capital Management, at USD 351m. The manager with the most riding on it is Kynam Capital Management, where it is 5.4% of the reported book.

Managers reporting it27of 720 we track
Value they reportUSD 696mshares only, 30 Jun 2026
Funds they run415with a file on PPLI.com
Largest positionUSD 351mFarallon Capital Management
Typical weight0.0%median share of a manager's book
Heaviest weight5.4%Kynam Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

27 managers, USD 696m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Beam Therapeutics Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Farallon Capital Management56 funds on PPLI.comUSD 351m1.6%
2Kynam Capital Management1 fund on PPLI.comUSD 97m5.4%
3Two Sigma Investments35 funds on PPLI.comUSD 48m0.0%
4Casdin Capital3 funds on PPLI.comUSD 46m2.3%
5Redmile Group10 funds on PPLI.comUSD 40m2.7%
6Deep Track Capital1 fund on PPLI.comUSD 34m0.5%
7RTW Investments2 funds on PPLI.comUSD 20m0.2%
8Marshall Wace LLP84 funds on PPLI.comUSD 16m0.0%
9Renaissance Technologies13 funds on PPLI.comUSD 15m0.0%
10Eversept Partners3 funds on PPLI.comUSD 5.7m0.3%
11D. E. Shaw & Co.15 funds on PPLI.comUSD 4.5m0.0%
12Edgestream Partners5 funds on PPLI.comUSD 3.3m0.1%
13Exoduspoint Capital Management7 funds on PPLI.comUSD 3.1m0.0%
14Schonfeld Strategic Advisors30 funds on PPLI.comUSD 1.8m0.0%
15Tudor Investment Corporation10 funds on PPLI.comUSD 1.7m0.0%
16Balyasny Asset Management25 funds on PPLI.comUSD 1.4m0.0%
17Millennium Management6 funds on PPLI.comUSD 1.2m0.0%
18Brevan Howard Capital Management39 funds on PPLI.comUSD 990,0000.0%
19Brandywine Managers47 funds on PPLI.comUSD 874,0000.4%
20Yiheng Capital Management1 fund on PPLI.comUSD 725,0000.2%
21Boothbay Fund Management2 funds on PPLI.comUSD 516,0000.0%
22Engineers Gate Manager1 fund on PPLI.comUSD 492,0000.0%
23Campbell & Company Investment Adviser8 funds on PPLI.comUSD 412,0000.0%
24Bayforest Capital1 fund on PPLI.comUSD 369,0000.3%
25Ivyrock Asset Management (HK)1 fund on PPLI.comUSD 295,0000.2%
26The Quarry1 fund on PPLI.comUSD 172,0000.0%
27Graticule Asia Macro Advisors8 funds on PPLI.comUSD 13,5910.0%
Next: where it matters most
Where it matters most

For Kynam Capital Management it is 5.4% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Kynam Capital ManagementUSD 97m5.4%
2Redmile GroupUSD 40m2.7%
3Casdin CapitalUSD 46m2.3%
4Farallon Capital ManagementUSD 351m1.6%
5Deep Track CapitalUSD 34m0.5%
6Brandywine ManagersUSD 874,0000.4%
7Bayforest CapitalUSD 369,0000.3%
8Eversept PartnersUSD 5.7m0.3%
9Yiheng Capital ManagementUSD 725,0000.2%
10RTW InvestmentsUSD 20m0.2%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Beam Therapeutics Inc.

What is the ticker symbol of Beam Therapeutics Inc.?

Beam Therapeutics Inc. trades under the symbol BEAM on the Nasdaq. Its CUSIP, the code used on Form 13F, is 07373V105.

Which hedge funds own Beam Therapeutics Inc. (Nasdaq: BEAM)?

27 of the 720 hedge fund managers PPLI.com tracks reported Beam Therapeutics Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Farallon Capital Management (USD 351m), Kynam Capital Management (USD 97m), Two Sigma Investments (USD 48m), Casdin Capital (USD 46m) and Redmile Group (USD 40m).

How many hedge funds hold Beam Therapeutics Inc.?

27 managers in our coverage reported it, and between them they run 415 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Beam Therapeutics Inc.?

Kynam Capital Management, where the position was 5.4% of the reported 13F book at 30 June 2026.

Does this show who is short Beam Therapeutics Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Beam Therapeutics Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.